Cargando…
Two-year outcomes of pro re nata ranibizumab monotherapy for exudative age-related macular degeneration in Japanese patients
PURPOSE: To describe outcomes of intravitreal ranibizumab using a pro re nata regimen for treatment-naive exudative age-related macular degeneration (AMD), in Japanese patients over the first 2 years. METHODS: Clinical records were retrospectively reviewed of 48 eyes of 48 patients with treatment-na...
Autores principales: | Yamamoto, Akiko, Okada, Annabelle A, Sugitani, Atsuhiko, Kunita, Daisuke, Rii, Tosho, Yokota, Reiji |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3633548/ https://www.ncbi.nlm.nih.gov/pubmed/23620657 http://dx.doi.org/10.2147/OPTH.S42189 |
Ejemplares similares
-
Intravitreal injection of ranibizumab using a pro re nata regimen for age-related macular degeneration and vision-related quality of life
por: Inoue, Maiko, et al.
Publicado: (2014) -
Results of switchback from ranibizumab to aflibercept in patients with exudative age-related macular degeneration
por: Koike, Naoko, et al.
Publicado: (2019) -
Initial Pro Re Nata Brolucizumab for Exudative AMD: The PROBE Study
por: Bilgic, Alper, et al.
Publicado: (2021) -
Ranibizumab plus fufang xueshuantong capsule versus ranibizumab alone
for exudative age-related macular degeneration
por: Pan, Hai-Tao, et al.
Publicado: (2020) -
Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab
por: Hamid, Mohamed A., et al.
Publicado: (2021)